MG

Miles Gerson

Head, Takeda Ventures

Cambridge, Massachusetts

Invests in

  • Min Investment:

    $1,000,000.00
  • Max Investment:

    $5,000,000.00
  • Target Investment:

    $2,500,000.00

Work Experience

  • Head, Takeda Ventures

    2024

    Takeda Ventures focuses on high-caliber, therapeutic, platform-based opportunities around the world. We invest in preclinical opportunities that complement Takeda’s pipeline and products. Our mission is to create strategic growth opportunities for Takeda by investing in and nurturing innovative, therapeutics companies in areas aligned with Takeda’s R&D foci which include; Oncology, Gastrointestinal, Inflammation and Neuroscience.

  • Executive Investment Director & Partner

    2023 - 2024

  • Senior Investment Director & Partner

    2021 - 2023

  • Partner

    2020 - 2021

  • Board Member

    2023

  • Board Member

    2021

  • Board Member

    2021

    Audit Committee

  • Board Member

    2022

  • Board Member

    2021

    Compensation Committee

  • Board Observer

    2021

2021 - 2022

  • Interim Head of GI Business Development

    2021 - 2022

    + Served in a dual role capacity on an interim basis to support Takeda’s GI BD team while Takeda sourced a new team lead. + Managed BD transaction team for preclinical and clinical transactions for TAK’s GI Drug Development and Therapeutic Area Units + Led and guided negotiations of term sheets through to deal structuring for collaborations & licensing + Responsible for advising on strategic transactions and management of existing partnerships

2021 - 2022

  • Board Member

    2021 - 2022

  • Senior Director, Business Development & Legal Affairs; Corporate Counsel and Compliance Officer

    2016 - 2020

    Formerly miRagen Therapeutics (NASDAQ:MGEN) + Member of MGEN’s Senior Leadership Team - Advising on corporate and commercial strategy + Head of Legal - Managed internal attorney team and multiple outside counsel internationally - Responsible for all legal and business term negotiations for all operational elements at MGEN - Supported Investor Relations and SEC compliance during and after MGEN’s reverse merger and listing on NASDAQ + Head of Business Development - Lead negotiator for term sheets, deal structuring for collaborations, and licensing - Responsible for strategic partnering, deal diligence, asset valuation, and market assessment - Lead for all partnering outreach across multiple therapeutic areas: oncology, cardiology, neurology, autoimmunity, dermatology, diabetes, fibrosis and ophthalmology